Thrombin@Fe3O4 nanoparticles for use as a hemostatic agent in internal bleeding
Autor: | Marina S. Kovalchuk, Andrey S. Drozdov, Emiliya M. Shabanova, Vladimir V. Vinogradov, Ivan P. Dudanov, Anna F. Fakhardo |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Internal bleeding
lcsh:Medicine Hemorrhage 02 engineering and technology 010402 general chemistry Ferric Compounds 01 natural sciences Article Hemostatics Thrombin X-Ray Diffraction medicine Humans lcsh:Science Blood Coagulation Hemostatic Agent Multidisciplinary Chemistry lcsh:R 021001 nanoscience & nanotechnology medicine.disease Thrombosis 0104 chemical sciences medicine.anatomical_structure Coagulation Hemostasis Nanoparticles lcsh:Q medicine.symptom 0210 nano-technology Blood vessel Biomedical engineering medicine.drug |
Zdroj: | Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Bleeding remains one of the main causes of premature mortality at present, with internal bleeding being the most dangerous case. In this paper, magnetic hemostatic nanoparticles are shown for the first time to assist in minimally invasive treatment of internal bleeding, implying the introduction directly into the circulatory system followed by localization in the bleeding zone due to the application of an external magnetic field. Nanoparticles were produced by entrapping human thrombin (THR) into a sol-gel derived magnetite matrix followed by grinding to sizes below 200 nm and subsequent colloidization. Prepared colloids show protrombotic activity and cause plasma coagulation in in vitro experiments. We also show here using a model blood vessel that the THR@ferria composite does not cause systematic thrombosis due to low activity, but being concentrated by an external magnetic field with simultaneous fibrinogen injection accelerates local hemostasis and stops the bleeding. For instance, a model vessel system with circulating blood at the puncture of the vessel wall and the application of a permanent magnetic field yielded a hemostasis time by a factor of 6.5 shorter than that observed for the control sample. Biocompatibility of composites was tested on HELF and HeLa cells and revealed no toxic effects. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |